Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of AQP4 functional variants and its association with fragile X-associated tremor/ataxia syndrome.
Elias-Mas A, Potrony M, Bague J, Cutler DJ, Alvarez-Mora MI, Torres T, Barcos T, Puig-Butille JA, Rubio M, Madrigal I, Puig S, Allen EG, Rodriguez-Revenga L. Elias-Mas A, et al. Among authors: rubio m. Front Aging Neurosci. 2023 Jan 6;14:1073258. doi: 10.3389/fnagi.2022.1073258. eCollection 2022. Front Aging Neurosci. 2023. PMID: 36688175 Free PMC article.
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit RB, Orvain C, Schroeder T, Bories C, Gurnari C, Badbaran A, Boyer-Perrard F, Pagliuca S, Rautenberg C, Tavitian S, Panagiota V, Ianotto JC, Thol FR, Cayssials E, Heuser M, Rubio MT, Cassinat B, Daltro de Oliveira R, Sauter CS, Maciejewski JP, Reinhardt HC, Scott BL, Ugo V, Kröger N, Kiladjian JJ, Robin M. Luque Paz D, et al. Among authors: rubio mt. Blood Adv. 2024 Nov 19:bloodadvances.2024014368. doi: 10.1182/bloodadvances.2024014368. Online ahead of print. Blood Adv. 2024. PMID: 39561372
Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24.
Savulescu C, Prats-Uribe A, Brolin K, Uusküla A, Bergin C, Fleming C, Murri R, Zvirbulis V, Zavadska D, Gaio V, Popescu CP, Hrisca R, Cisneros M, Latorre-Millán M, Lohur L, McGrath J, Ferguson L, De Gaetano Donati K, Abolina I, Gravele D, Machado A, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sui J, Kenny C, Santangelo R, Krievins D, Barzdina EA, Valadas Henriques C, Kosa AG, Pohrib SM, Muñoz-Almagro C, Milagro A, Bacci S, Nardone A; VEBIS HCW VE study group; Collaborators in VEBIS HCW study group. Savulescu C, et al. Euro Surveill. 2024 Oct;29(44):2400680. doi: 10.2807/1560-7917.ES.2024.29.44.2400680. Euro Surveill. 2024. PMID: 39484687 Free PMC article.
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A, Kristensen LE; STEP 9 Study Group. Bliddal H, et al. N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664. N Engl J Med. 2024. PMID: 39476339 Clinical Trial.
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.
Angelillo P, Alarcon Tomas A, Campodonico E, Novak U, Gabellier L, Blau IW, Kwon M, Ram R, Forcade E, Besley C, Vucinic V, Kröger N, Corral LL, Vydra J, Ferrari S, von Tresckow B, Rubio MT, Hernani R, Sica S, Stölzel F, Rovira M, Wagner-Drouet E, Pérez-Simón JA, Castilla-Llorente C, Ferreri AJM, Hoogenboom JD, Sanchez Ortega I, Malard F, Kuball J, Ruggeri A. Angelillo P, et al. Among authors: rubio mt. Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02451-8. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39455896 No abstract available.
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
García-Donas J, Redondo A, Santaballa A, Garrigos L, Rubio MJ, Lainez N, González MI, Cueva JF, Barquin A, Grazioso TP, Hurtado A, Sevillano E, Grande E, Rodriguez-Moreno JF, Navarro P. García-Donas J, et al. Among authors: rubio mj. Gynecol Oncol. 2024 Oct 24;191:233-239. doi: 10.1016/j.ygyno.2024.10.019. Online ahead of print. Gynecol Oncol. 2024. PMID: 39454227
1,803 results